Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1B Rx Improves Insulin Sensitivity and Reduces Weight in Overweight Patients With Type 2 Diabetes
To evaluate safety and efficacy of IONIS-PTP-1B , a second-generation 2'- -methoxyethyl antisense inhibitor of protein tyrosine phosphatase 1B, as add-on therapy in overweight patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea therapy. In this phas...
Saved in:
Published in | Diabetes care Vol. 41; no. 4; p. 807 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.04.2018
|
Online Access | Get full text |
Cover
Loading…
Summary: | To evaluate safety and efficacy of IONIS-PTP-1B
, a second-generation 2'-
-methoxyethyl antisense inhibitor of protein tyrosine phosphatase 1B, as add-on therapy in overweight patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea therapy.
In this phase II, double-blind, randomized, placebo-controlled, multicenter trial, overweight and obese patients (BMI ≥27 kg/m
) with type 2 diabetes (HbA
≥7.5% [58 mmol/mol] and ≤10.5% [91 mmol/mol]) on a stable dose of metformin alone or with sulfonylurea were randomized 2:1 to IONIS-PTP-1B
200 mg (
= 62) or placebo (
= 30) once weekly for 26 weeks.
Mean baseline HbA
was 8.6% (70 mmol/mol) and 8.7% (72 mmol/mol) in placebo and active treatment, respectively. At week 27, IONIS-PTP-1B
reduced mean HbA
levels by -0.44% (-4.8 mmol/mol;
= 0.074) from baseline and improved leptin (-4.4 ng/mL;
= 0.007) and adiponectin (0.99 μg/mL;
= 0.026) levels compared with placebo. By week 36, mean HbA
was significantly reduced (-0.69% [-7.5 mmol/mol];
= 0.034) and accompanied by reductions in fructosamine (-33.2 μmol/L;
= 0.005) and glycated albumin (-1.6%;
= 0.031) versus placebo. Despite both treatment groups receiving similar lifestyle counseling, mean body weight significantly decreased from baseline to week 27 with IONIS-PTP-1B
versus placebo (-2.6 kg;
= 0.002) independent of HbA
reduction (
= 0.0020). No safety concerns were identified in the study.
Compared with placebo, IONIS-PTP-1B
treatment for 26 weeks produced prolonged reductions in HbA
, improved medium-term glycemic parameters, reduced leptin and increased adiponectin levels, and resulted in a distinct body weight-reducing effect. |
---|---|
ISSN: | 1935-5548 |